Table 1 Baseline characteristics of eligible studies
From: The value of urinary gonadotropins in the diagnosis of central precocious puberty: a meta-analysis
Author (Year) | Country | Gold standard | Serum Gn | Urinary Gn | UGn corrected or not | Inclusion criteria | Sample size | Age (y) | Blind or not |
|---|---|---|---|---|---|---|---|---|---|
Shim, YS 2019 [11] | Korea | GnRH ECLIA Stimulation testa | DELFIA | No | Tanner breast stage ≥ 2; an advanced bone age (BA) by > 1 year | 100 | 6.0–8.9 | Yes | |
Kolby, N 2017 [12] | Denmark | GnRH Stimulation test | IFMA | IFMA | Yes | Tanner breast stage ≥ 2 | 25 | < 8.0 | Yes |
Yang, QH | China | GnRH Stimulation test | Not mentioned | CLIA | No | Tanner breast stage ≥ 2; an advanced BA by ≥ 1 year; Accelerated growth | 184 | 6.0–10.0 (6.7 ± 0.5) | Yes |
Chen, Y | China | GnRH Stimulation test | Not mentioned | ICA | Yes | Tanner breast stage ≥ 2; an advanced BA by ≥ 1 year; Accelerated growth | 70 | < 10.0 (7.12 ± 1.99) | Yes |
Ma, XY | China | GnRH Stimulation test | CMA | ICA | Yes | Tanner breast stage ≥ 2; an advanced BA by ≥ 1 year; Accelerated growth | 49 | 4.0–8.0 (7.41 ± 1.48) | Yes |
Zhang, TT | China | GnRH Stimulation test | ICMA | ICMA | No | Tanner breast stage ≥ 2; an advanced BA by ≥ 1 year | 63 | (8.44 ± 1.20) | Yes |